Opinion | January 13, 2022
Outlook for the Indian Pharma Industry remains stable for this year
The stability is led by healthy demand in the domestic and emerging markets
The stability is led by healthy demand in the domestic and emerging markets
Ind-Ra expects revenue growth of over 12% in 2022.
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
It is the generic version of molnupiravir
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Subscribe To Our Newsletter & Stay Updated
